<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192595</url>
  </required_header>
  <id_info>
    <org_study_id>VHWG001</org_study_id>
    <secondary_id>TICO</secondary_id>
    <nct_id>NCT00192595</nct_id>
  </id_info>
  <brief_title>Tenofovir in HIV/HBV Coinfection</brief_title>
  <acronym>TICO</acronym>
  <official_title>Virological and Clinical Anti-HBV Efficacy of Tenofovir in Antiretroviral na誰ve Patients With HIV/HBV Co-infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the effectiveness of 3 different treatment regimens in
      reducing or clearing the Hepatitis B Virus in patients infected with HIV and Hepatitis B
      (co-infection)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised multi-centre trial of tenofovir vs lamivudine vs tenofovir/lamivudine in
      antiretroviral na誰ve subjects with HIV/HBV co-infection over 48 weeks (Clinical Trial A).
      Plus, a 12 week viral kinetic sub-study comparing a sub-group of the patients on Clinical
      Trial A with a group of therapy na誰ve HBV mono-infected subjects (Substudy A1)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare HBV DNA suppression to levels below the limit of detection (&lt;400 copies/ml) by week 48 in each group</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>-HBV resistance at 48 weeks; -undetectable HBV DNA at weeks 12 &amp; 24; -HBeAg and HBsAg seroconversion at weeks 24 &amp; 48; -ALT chnages and rate of hepatic cytolysis; -HIV-1 RNA supression and CD4/CD8 changes over 48 weeks;</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>HIV Infection</condition>
  <condition>Hepatitis B Coinfection</condition>
  <arm_group>
    <arm_group_label>Arm 1:</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zidovudine (AZT), tenofovir (TDF), efavirenz (EFV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amr 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lamivudine (LAM), tenofovir (TDF), efavirenz (EFV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Amr 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)</intervention_name>
    <arm_group_label>Arm 1:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Documented HIV infection (positive serology for HIV-1 and detectable HIV-1 RNA)

          -  Age 18 - 70 years

          -  HBV DNA &gt; 105 copies/ml

          -  HBsAg positive &gt;6 months or HBsAg positive and anti HB core IgM negative

          -  Creatinine &lt;= 2.0mg/dl (&lt;= 0.2 mmol/L)

          -  Platelet count &gt;= 50,000/mm

          -  HIV-1 antiretroviral therapy na誰ve

          -  No prior exposure to anti-HBV agents (LAM, adefovir, TDF) although prior IFN treatment
             allowed

        Exclusion Criteria:

          -  HCV-RNA positive or Anti-HAV IgM positive

          -  Acute hepatitis (serum ALT &gt; 1000 U/L)

          -  Active opportunistic infection

          -  Other causes of chronic liver disease identified (autoimmune hepatitis,
             hemochromatosis, Wilsons disease, alfa-1-antitrypsin deficiency)

          -  Concurrent malignancy requiring cytotoxic chemotherapy

          -  Decompensated or Child's C cirrhosis

          -  Alfa-fetoprotein (AFP) &gt; 3X ULN (unless negative CT scan or MRI within 3 months of
             entry date)

          -  Pregnancy or lactation

          -  Any other condition which in the opinion of the investigator might interfere with
             compliance or outcome of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Dore, MBBS, FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Centre in HIV Epidemiology and Clinical Research.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <name_title>A/Prof Gregory J Dore</name_title>
    <organization>National Centre in HIV Epidemiology and Clinical Research, Univeristy of New South Wales</organization>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>HIV</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

